Company profile: Solarea Bio
1.1 - Company Overview
Company description
- Provider of microbial therapeutics and microbial-based solutions targeting chronic inflammation. Develops Defined Microbial Assemblage products combining probiotic microbes from fruits and vegetables with prebiotic fibers, advances medical foods, and creates synbiotics to protect against bone loss. Also offers licensing of its microbial-based technology, including a technology licensing agreement with ADM.
Products and services
- Microbial-Based Products for Chronic Inflammation (indication-focused): Architects microbial-based products aimed to treat indications derived from chronic inflammation to aid human health, focusing development on inflammation-driven conditions and therapeutic applications
- Defined Microbial Assemblage (DMA) Technology (modular): Engineers products combining probiotic microbes from fruits and vegetables with prebiotic fibers, creating defined microbial assemblies pairing beneficial microbes with prebiotic fiber ingredients
- Synbiotic for Bone Health (custom-formulated): Develops a synbiotic to protect against bone loss, indicating targeted bone health products addressing skeletal integrity and loss prevention
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Solarea Bio
Xycrobe
HQ: United States
Website
- Description: Provider of early-stage biotechnology research and development leveraging extensive human microbiome data to develop novel therapies for clinical applications, with innovations that utilize microbes as delivery vehicles.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Xycrobe company profile →
Biocontrol
HQ: United Kingdom
Website
- Description: Provider of a novel system using biological agents to control bacterial infections by Pseudomonas aeruginosa, with proven efficacy and safety even where conventional antibiotics have failed.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Biocontrol company profile →
Vedanta Biosciences
HQ: United States
Website
- Description: Provider of microbiome-derived therapies that modulate the gut microbiota to address immune and infectious diseases via orally administered defined bacterial consortia. Pipeline includes VE303 for preventing Clostridioides difficile infection recurrence (Phase 2 met primary efficacy endpoint), VE202 for IBD, and VE707 for MDROs (including CRE, ESBL, VRE); backed by CARB-X research grants.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vedanta Biosciences company profile →
Kallyope
HQ: United States
Website
- Description: Provider of medicines developed using the science of gut-brain biology to transform human health.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kallyope company profile →
Infinant Health
HQ: United States
Website
- Description: Provider of infant gut microbiome solutions, offering Evivo Powder, a daily supplement for infants fed any amount of breast milk to establish a protective gut microbiome and support healthy immune function, and B. infantis EVC001, a bacterial strain discovered by Infinant Health and proven pivotal to infant immune health, particularly when combined with breast milk.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Infinant Health company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Solarea Bio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Solarea Bio
2.2 - Growth funds investing in similar companies to Solarea Bio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Solarea Bio
4.2 - Public trading comparable groups for Solarea Bio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →